Posted by Marion Hillson on Mar 19th, 2024
Geron (NASDAQ:GERN – Free Report) had its target price lifted by Needham & Company LLC from $4.00 to $5.00 in a report issued on Friday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the biopharmaceutical...
More of this article »